Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.00 Average PT from Brokerages

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $7.00.

Several brokerages have commented on ESPR. Wall Street Zen lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 25th. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, September 19th.

Esperion Therapeutics Stock Up 5.3%

Shares of ESPR opened at $2.56 on Friday. The stock has a market capitalization of $516.15 million, a P/E ratio of -5.22, a PEG ratio of 54.58 and a beta of 0.89. The firm has a fifty day simple moving average of $2.08 and a two-hundred day simple moving average of $1.45. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.15. The business had revenue of $82.39 million during the quarter, compared to analysts’ expectations of $62.55 million. Esperion Therapeutics had a negative net margin of 35.84% and a negative return on equity of 0.91%. Sell-side analysts expect that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ESPR. North Star Investment Management Corp. bought a new position in Esperion Therapeutics in the 2nd quarter worth $25,000. Sivia Capital Partners LLC bought a new position in shares of Esperion Therapeutics in the 2nd quarter worth about $25,000. Meridian Wealth Management LLC bought a new position in shares of Esperion Therapeutics in the 1st quarter worth about $29,000. Synergy Asset Management LLC increased its stake in shares of Esperion Therapeutics by 3,496.3% in the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 30,138 shares in the last quarter. Finally, Boomfish Wealth Group LLC increased its stake in shares of Esperion Therapeutics by 29.5% in the 2nd quarter. Boomfish Wealth Group LLC now owns 45,306 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 10,309 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.